Actinogen Medical Ltd has released a press release.
FDA IND Update
Filed with ASX ·
On 6ix: 6ix.com/news/fda-ind-update
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW to initiate XanaFX clinical trial in Fragile X syndrome
- R&D Tax Incentive Rebate received of A$2.9 million
- Offer Booklet
- Actinogen Presentation & Planned Conference Call
- Proposed issue of Securities - ACW
Later from Actinogen Medical
- Actinogen files new patent applications
- Completion of Entitlement Offer
- FDA Grants ACW Rare Paediatric Disease Designation in FXS
- Resignation of Dr Bill Ketelbey as Chief Executive Officer
- ACW raises an addtional $3.55m under a Shortfall Placement
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical